JRJulie A. Ross

Julie A. Ross

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julie A. Ross has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Genetic susceptibility and body mass in childhood cancer survivors

    by Julie A. Ross

    Childhood cancer survivors are at increased risk of many long‐term treatment‐related sequel such as second cancers, cardiovascular disease, and pulmonary complications. Certain treatments seem to influence the risk of becoming overweight, obese, or underweight, and abnormal body mass index (BMI) is associated with increased morbidity and mortality. Because BMI is modifiable, it is important to identify treatment and patient‐related factors contributing to altered BMI. New research areas include exploring how genetic susceptibility through population polymorphism may contribute to BMI. Illuminating potential gene–environment interactions that influence obesity and underweight might be more readily accomplished in a study of high‐risk individuals (i.e., childhood cancer survivors) with well‐characterized exposures. The new Childhood Cancer Research Network in the Children's Oncology Group, when fully implemented, should make it less difficult in the future to recruit the large numbers of patients needed for such studies. Pediatr Blood Cancer 2007;48:731–735.


  • Open Access

    Infant Leukemia: Finding the Needle in the Haystack

    by Logan G. Spector, Julie A. Ross

    Historically, the study of rare malignancies, including retinoblastoma, angiosarcoma, and vaginal clear cell carcinoma, has led to major findings in our understanding of cancer etiology. Leukemias that occur in children less than 1 year of age likely represent another rare group that could potentially lead to further understanding of carcinogenesis. The vast majority of infants present with a genetic abnormality in their leukemia cells that affects the MLL gene on chromosome band 11q23, and a substantial body of evidence supports the contention that these MLL abnormalities (mostly rearrangements) occur in utero (1). Thus, the window of exposure is very brief. We and others have shown that specific environmental exposures (2, 3) and genotypes (4-7) may be unique to these MLL abnormalities in infant leukemias. Here, Pombo-de-Oliveira et al. (8) demonstrate an association between infant leukemia and maternal hormone use before and during pregnancy, which appeared to vary by timing of exposure and MLL status. The authors further show an association of MLL-positive infant leukemia with quinolones, which, although imprecise, is interesting given these drugs that interact with DNA topoisomerase II (9). These results support differing etiologies for molecularly defined subtypes of infant leukemia. Rarity is the major obstacle to elucidating translocation-specific risk factors but may be overcome by cooperative group participation (10) and international collaboration. Epidemiologic investigations may also be informed by mechanistic studies, which have sought to correlate prenatal exposures with the frequency of MLL transcripts or chromosome breakage at the 11q23 locus in cord blood (11, 12). Thus, we expect big developments from this small cancer.


  • Open Access

    Maternal hemoglobin concentration during pregnancy and risk of infant leukaemia: a children's oncology group study

    by A M Peters, C K Blair, M R Verneris, J P Neglia, L L Robison, L G Spector, G H Reaman, C A Felix, J A Ross

    In contrast to the positive association found in three studies between maternal anaemia during pregnancy and childhood leukaemia, no such association was found in infant leukaemia (odds ratio 0.85, 95% confidence interval 0.53–1.37).


  • Childhood Leukemias

    by Ching-Hon Pui, Donald Pinkel, Mihaela Onciu, Logan G. Spector, Julie A. Ross, Leslie L. Robison, Smita Bhatia, Connie J. Eaves, Allen C. Eaves, James N. Ihle, et al.

    Childhood leukemias represent nearly one third of all cancers in children and present a unique challenge to oncologists, pediatricians, hematologists, and other health professionals. Dr Ching-Hon Pui has assembled an expert team of authors to develop the most comprehensive, clinically-oriented, and authoritative reference dedicated to these diseases. Childhood Leukemias moves from the laboratory bench to the patient bedside in four easily-accessible sections. Part one presents an historical overview, whilst part two presents an in-depth review of topics needed to understand the pathobiology of leukemia. Part three builds upon this scientific foundation by explaining practical approaches to clinical diagnosis, evaluation, and treatment, and part four outlines major clinical complications which may arise during and after treatment, along with chapters on supportive care, psychosocial issues, and nursing. Fully referenced and up-to-date, Childhood Leukemias is an absolute 'must-have' for any physician or investigator who deals with leukemias in childhood.


  • XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report

    by Parinda A. Mehta, Todd A. Alonzo, Robert B. Gerbing, James S. Elliott, Tiffany A. Wilke, Rebekah J. Kennedy, Julie A. Ross, John P. Perentesis, Beverly J. Lange, Stella M. Davies

    Genetic polymorphisms result in interindividual variation in DNA repair capacity and may, in part, account for susceptibility of a cell to genotoxic agents and to malignancy. Polymorphisms in XPD, a member of the nucleotide excision repair pathway, have been associated with development of treatment-related acute myeloid leukemia (AML) and with poor outcome of AML in elderly patients. We hypothesized that XPD Lys751Gln polymorphism may play a role in causation of AML in children and, as shown in adults, may affect the outcome of childhood AML therapy. Genotyping of 456 children treated for de novo AML was performed at XPD exon 23. Genotype frequencies in patients were compared with healthy control subject frequencies, and patient outcomes were analyzed according to genotype. Gene frequencies in AML patients and healthy controls were similar. There were no significant differences in overall survival (P = .82), event-free survival (P = .78), treatment-related mortality (P = .43), or relapse rate (RR) (P = .92) between patients with XPD751AA versus 751AC versus 751CC genotypes, in contrast to reports in adult AML. These data, representing the only data in pediatric AML, suggest that XPD genotype does not affect the etiology or outcome of childhood AML.


  • Open Access

    Periconceptional vitamin use and leukemia risk in children with Down syndrome

    by Julie A. Ross, Cindy K. Blair, Andrew F. Olshan, Leslie L. Robison, Franklin O. Smith, Nyla A. Heerema, Michelle Roesler

    BACKGROUND: Periconceptional vitamin supplementation reduces the risk of neural tube defects, and possibly may reduce the risk of certain childhood malignancies, including acute lymphoblastic leukemia (ALL). Because children with Down syndrome (DS) experience a 20‐fold higher risk of leukemia than the general population, the authors evaluated whether periconceptional vitamin supplementation reduced the risk of leukemia in children with DS.METHODS: From 1997 to 2002, 158 children ages birth–18 years with DS and acute leukemia (n = 61 children with acute myeloid leukemia [AML] and n = 97 children with ALL) were enrolled through the Children's Oncology Group in North America. Children with DS alone (n = 173) were identified through the cases' pediatric clinics and frequency matched to cases on age. Mothers of cases and controls completed a telephone interview that included questions regarding vitamin supplement use in the periconceptional period and after knowledge of pregnancy.RESULTS: A decreased risk of leukemia was observed with vitamin supplementation in the periconceptional period (odds ratio [OR] = 0.63; 95% confidence interval [95% CI], 0.39–1.00). When stratified by leukemia type, the reduced risk was observed for ALL (OR = 0.51; 95% CI, 0.30–0.89), but not for AML (OR = 0.92; 95% CI, 0.48–1.76). Compared with vitamin use in the periconceptional period, use only after knowledge of pregnancy was associated with an increased risk of leukemia (OR = 1.61; 95% CI, 1.00–2.58). This was observed for both ALL and AML.CONCLUSIONS: These data added to a growing body of evidence that suggests that periconceptional vitamin use may be protective in the development of certain childhood cancers. Cancer 2005. © 2005 American Cancer Society.


  • Hormone replacement therapy is not associated with an increased risk of leukemia (United States)

    by Julie A. Ross, Penny J. Sinner, Cindy K. Blair, James R. Cerhan, Aaron R. Folsom


  • Etiology of childhood cancer: Recent reports

    by Julie A. Ross, Logan G. Spector, Stella M. Davies